Cancer therapy using interleukin-2 and flavone compounds

• US 5,126,129 A
• Filed: 02/04/1991
• Issued: 06/30/1992
• Est. Priority Date: 05/23/1988
• Status: Expired due to Term

• Current Assignee: The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: The United States of America As Represented By The Secretary of Agriculture
• Inventors: Hornung, Ronald, Wiltrout, Robert H.
• Primary Examiner(s): FRIEDMAN, STANLEY
• Application Number:
  US07/649,182
• Time in Patent Office: 512 Days
• Field of Search: 514/456, 424/85.2
• US Class Current: 424/85.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/35 having six-membered rings with one oxygen as the only ring hetero atom
• CPC Class Codes: A61K 38/20 Interleukins [IL]
• CPC Class Codes: A61K 38/2013 IL-2

Abstract

Treatment of Cancer with Flavones and Interleukin 2.

Claims

1. A method for treating cancers which are susceptible to treatment with a combination of compounds provided herein, the method comprising administering by injection to a host the combination of:

an effective amount of a flavone compound of the formula;

##STR4## in which AR is phenyl substituted by lower alkyl or lower alkoxy, or AR is thienyl, or furyl;

R₁ is hydrogen;

B is a lower linear or branched alkylene or alkenylene radical;

X is hydrogen, lower alkyl or lower alkoxy;

n equals 1;

R₂ is hydrogen, a lower dialkylamino, lower alkyl or morpholinoethyl for treating said cancer;

or an alkali metal salt of said acid;

and an effective amount of interleukin 2 for treating said cancer.

2. The method of claim 1 wherein the cancer is renal carcinoma.

3. The method of claim 1 wherein the flavones are administered prior to administration of the interleukin 2.

4. The method of claim 3 wherein the interleukin 2 is administered in at least 4 daily doses.

5. The method of claim 1 wherein the flavones are administered in amounts ranging from about 100 mg/kg body weight to about 500 mg/kg body weight.

6. The method of claim 5 wherein the flavones are administered intravenously.

7. The method of claim 5 wherein the flavones are administered intraperitoneally.

8. The method of claim 1 wherein the treatment agents are administered by a combination of intraperitoneal and intravenous administration.

9. A method of claim 1 wherein the flavone given is a compound of the formula:

##STR5## or its sodium salt.

15. The method for treating cancers recited in claim 1, wherein:

Ar is phenyl substituted by lower alkyl or lower alkoxy.

16. The method for treating cancers recited in claim 1, wherein:

Ar is phenyl substituted by lower alkyl or lower alkoxy;

X is hydrogen; and

R₂ is hydrogen.

10. A method for treating renal carcinomas, comprising administering by injection to a host an effective amount of a flavone compound of the formula:

##STR6## or an alkali metal salt thereof; and

an effective amount of interleukin 2.

11. The method of claim 10, wherein the alkali metal salt is the sodium salt.

12. A synergistic pharmaceutical composition for the treatment of cancers which are susceptible to treatment therewith, the composition comprising an effective amount of a flavone compound of the formula:

##STR7## in which AR is phenyl substituted by lower alkyl or lower alkoxy, or AR is thienyl, or furyl;

R₁ is hydrogen;

B is a lower linear or branched alkylene or alkenylene radical;

X is hydrogen, lower alkyl or lower alkoxy;

n equals 1;

R₂ is hydrogen, a lower dialkylamino, lower alkyl or morpholinoethyl for treating the cancer;

or an alkali metal salt of said acid; and

an effective amount of interleukin-2 for treating the cancer; and

a pharmaceutically acceptable carrier therefor.

13. The synergistic pharmaceutical composition of claim 12, wherein said flavone compound is ##STR8## or an alkali metal salt thereof.

14. The synergistic pharmaceutical composition of claim 13, wherein the alkali metal salt is the sodium salt.

17. The synergistic pharmaceutical composition recited in claim 12, wherein:

Ar is phenyl substituted by lower alkyl or lower alkoxy.

18. The synergistic pharmaceutical composition recited in claim 12, wherein:

Ar is phenyl substituted by lower alkyl or lower alkoxy;

X is hydrogen; and

R₂ is hydrogen.